Compare JEF & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | FMS |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 13.6B |
| IPO Year | 2017 | 2005 |
| Metric | JEF | FMS |
|---|---|---|
| Price | $47.64 | $22.69 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $61.40 | $30.00 |
| AVG Volume (30 Days) | ★ 1.8M | 635.7K |
| Earning Date | 03-25-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.37% | 2.57% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | N/A |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $10.25 | $3.83 |
| P/E Ratio | $66.06 | ★ $15.62 |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $35.53 | $20.02 |
| 52 Week High | $69.93 | $27.64 |
| Indicator | JEF | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 48.19 |
| Support Level | $45.78 | $22.37 |
| Resistance Level | $49.52 | $23.99 |
| Average True Range (ATR) | 1.80 | 0.28 |
| MACD | -0.36 | 0.05 |
| Stochastic Oscillator | 23.84 | 65.32 |
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.